Search research articles
Contact Us
Filters
Showing results (141-150 of 159) with videos related to
Page
of 16
Sort By:
Circulation
|
December 1, 1991
Catecholamine metabolic pathways and exercise training. Plasma and urine catecholamines, metabolic enzymes, and chromogranin-A
P J Rogers, G M Tyce, R M Weinshilboum, et al.
Federation Proceedings
|
July 1, 1986
Amine sulfate formation in the central nervous system
G M Tyce, J M Messick, T L Yaksh, et al.
Neurology
|
March 1, 1996
Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease
J E Ahlskog, R J Uitti, P A Low, et al.
Advances in Pharmacology (San Diego, Calif.)
|
November 5, 1997
The adrenal gland as a source of dihydroxyphenylalanine and catecholamine metabolites
G M Tyce, S L Chritton, R D Barnes, et al.
The Journal of Laboratory and Clinical Medicine
|
December 14, 1999
Dopamine enhances the phosphaturic effect of PTH during acute respiratory alkalosis
T J Berndt, R R Tucker, P D Kent, et al.
Neuroscience
|
July 18, 2001
Nitric oxide modulates evoked catecholamine release from canine adrenal medulla
R D Barnes, L E Ward, K P Frank, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
August 5, 2003
L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients
M K Dousa, R M Weinshilboum, M D Muenter, et al.
Experimental Neurology
|
October 1, 1991
Decreased levels of [Met]enkephalin, neuropeptide Y, substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla
S L Stoddard, G M Tyce, J E Ahlskog, et al.
Experimental Neurology
|
August 1, 1989
Cerebrospinal fluid indices of blood-brain barrier permeability following adrenal-brain transplantation in patients with Parkinson's disease
J E Ahlskog, G M Tyce, P J Kelly, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 1, 1995
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease
J E Ahlskog, R J Uitti, P A Low, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 159) with videos related to
Sort By:
Page
of 16
Circulation
|
December 1, 1991
Catecholamine metabolic pathways and exercise training. Plasma and urine catecholamines, metabolic enzymes, and chromogranin-A
P J Rogers, G M Tyce, R M Weinshilboum, et al.
Federation Proceedings
|
July 1, 1986
Amine sulfate formation in the central nervous system
G M Tyce, J M Messick, T L Yaksh, et al.
Neurology
|
March 1, 1996
Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease
J E Ahlskog, R J Uitti, P A Low, et al.
Advances in Pharmacology (San Diego, Calif.)
|
November 5, 1997
The adrenal gland as a source of dihydroxyphenylalanine and catecholamine metabolites
G M Tyce, S L Chritton, R D Barnes, et al.
The Journal of Laboratory and Clinical Medicine
|
December 14, 1999
Dopamine enhances the phosphaturic effect of PTH during acute respiratory alkalosis
T J Berndt, R R Tucker, P D Kent, et al.
Neuroscience
|
July 18, 2001
Nitric oxide modulates evoked catecholamine release from canine adrenal medulla
R D Barnes, L E Ward, K P Frank, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
August 5, 2003
L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients
M K Dousa, R M Weinshilboum, M D Muenter, et al.
Experimental Neurology
|
October 1, 1991
Decreased levels of [Met]enkephalin, neuropeptide Y, substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla
S L Stoddard, G M Tyce, J E Ahlskog, et al.
Experimental Neurology
|
August 1, 1989
Cerebrospinal fluid indices of blood-brain barrier permeability following adrenal-brain transplantation in patients with Parkinson's disease
J E Ahlskog, G M Tyce, P J Kelly, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 1, 1995
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease
J E Ahlskog, R J Uitti, P A Low, et al.
Page
of 16